A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)

The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.

Inclusion Criteria:

• Chemotherapy-naive patients who are histologically or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV
• Patients with normal organ function and bone marrow function

Exclusion Criteria:

• Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks
• Any peripheral neuropathy above grade 2
• Any ascites, pleural effusion or pericardiac effusion which requires treatment
• Any uncontrolled concomitant illness
• Pregnant or breast-feeding